According to the ToGA trial (a large, multicenter, phase III, randomized controlled trial), trastuzumab in combination with chemotherapy is the new standard option for patients with HER2+ advanced gastric and GEJ adenocarcinoma, due to its survival benefit (6). The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.